BioSpace News Archive

Rhia Ventures’ impact venture capital fund - RH Capital Fund II - announces its investment in OCON Healthcare to bring safer, more affordable contraception options to women in the US

-- Oral XPOVIO Now Available as a Treatment Option for Patients with Multiple Myeloma As Early as First Relapse; Significantly Expands Addressable Patient Population -- -- Oral XPOVIO is Now the Only Multiple Myeloma Drug Indicated as Part of an Approved, Once-Weekly Velcade® (bortezomib) Combination Regimen -- -- First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 -

Underwriters Exercise Over-Allotment Option in Full IPO Proceeds for Further Development of Company’s Novel, Targeted Immuno-Oncology Gene Therapy for Multiple Cancers

Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan’s favor in the lawsuit brought against it by Sanofi related to its EpiPen® products. Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi’s baseless attempts

Topical drugs delivery includes treatment of body surface such as outer membrane or skin. The drugs are in the form of solid, semi-solid, liquid, gel, and transdermal patches.

The rising incidences of progressive Supranuclear palsy worldwide are a key factor aiding in expansion of the global progressive Supranuclear palsy treatment market.

The global airway management devices are medical devices used for patients have obstructed airways or are at the risk of being obstructed.

Physical therapy involves various techniques employed to alleviate pain and bring mobility to injured human body parts such as limbs and joints.

Hydrolases are enzymes that catalyze the breakdown of chemical bonds in the presence of water. Common examples of hydrolase enzymes are esterases including lipases, phosphatases, glycosidases, peptidases, and nucleosidases.

Antengene Corporation Limited announced that the National Medical Products Administration has approved the Investigational New Drug application for ATG-010, an oral Selective Inhibitor of Nuclear Export compound, in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma in China.